Methylation data from stored peripheral blood leukocytes from African American participants in the GENOA study with Infinium HumanMethylationEPIC BeadChip
The Genetic Epidemiology Network of Arteriopathy (GENOA) study is a community-based study of hypertensive sibships that was designed to investigate the genetics of hypertension and target organ damage. The study includes African Americans (AA) from Jackson. In the initial phase of GENOA (Phase I: 1996-2001), all members of sibships containing at least 2 individuals with essential hypertension clinically diagnosed before age 60 were invited to participate, including both hypertensive and normotensive siblings. The exclusion criteria for GENOA included secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. Eighty percent of AA (N=1,482) from the initial study population returned for the second examination (Phase II: 2001-2005). Demographic information, medical history, clinical characteristics, lifestyle factors, and blood samples were collected in each phase. Written informed consent was obtained from all subjects and approval was granted by participating institutional review boards (University of Michigan, University of Mississippi Medical Center, and Mayo Clinic). Genomic DNA was extracted from stored peripheral blood leukocytes that was collected at Phase 1 (N=1106) or Phase 2 (N=304) using AutoGen FlexStar (AutoGen, Holliston, MA). Bisulfite conversion was performed with the EZ DNA Methylation Kit (Zymo Research, Irvine, CA), and methylation was assessed using the Illumina Infinium HumanMethylationEPIC BeadChip. In total 1,394 samples remained after quality control and filtering.
Less...
More...